Skip to main content

French Study Supports Cetuximab in Esophageal Cancer

Cetuximab (Erbitux) may be an active addition to chemoradiation and chemotherapy for the treatment of locally advanced esophageal cancer, according to the final results of an open-label, single-arm multicenter phase II study conducted in France by the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR).1

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino